NovaBay Pharmaceuticals, Inc. Share Price Nyse
Equities
US66987P1021
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
06-21 | NovaBay Files Registration Statement on Behalf of Selling Shareholders | MT |
05-09 | NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 13.6M 1.08B | Sales 2025 * | 18.72M 1.48B | Capitalization | 2.55M 201M |
---|---|---|---|---|---|
Net income 2024 * | -5M -395M | Net income 2025 * | - 0 | EV / Sales 2024 * | 0.19 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.14 x |
P/E ratio 2024 * |
-0.37
x | P/E ratio 2025 * |
-6.31
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.96% |
Latest transcript on NovaBay Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Justin Hall
CEO | Chief Executive Officer | 46 | 31/01/13 |
Tommy Law
DFI | Director of Finance/CFO | 38 | 30/11/19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Freiman
CHM | Chairman | 89 | 30/04/02 |
Yen You Zheng
BRD | Director/Board Member | 67 | 10/09/19 |
Bob Wu
BRD | Director/Board Member | 49 | 25/01/16 |
1st Jan change | Capi. | |
---|---|---|
+19.41% | 45.51B | |
-8.62% | 38.52B | |
+38.65% | 38.13B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |